20 articles
New study shows clearing senescent cells with Navitoclax improves heart function and reduces inflammation in heart failure with preserved ejection fraction.
A new review examines how drugs that clear senescent cells could transform treatment of age-related cardiovascular disease.
Not all fibrates work the same way — fenofibrate uniquely reduces apoB, cutting residual cardiovascular risk beyond statins alone.
A sirtuin enzyme prevents heart scarring by keeping cardiac fibroblasts from switching to a pro-fibrotic metabolic state.
New research shows inhibiting fatty acid synthase prevents cardiac hypertrophy and restores heart function in multiple models.
Natural isoflavone prevents cardiac enlargement through novel mitochondrial protection pathway, offering new therapeutic approach.
Real-world study of 1,559 octogenarians finds SGLT2 inhibitors reduce all-cause death by 42% and heart failure rehospitalization by 31% with no increase in adverse events.
A new review reveals how sirtuin enzymes regulate cardiac fibrosis and why targeting them could reshape heart failure treatment.
Sotatercept emerges as potential treatment for combined pre-capillary pulmonary hypertension and heart failure with preserved ejection fraction.
New research reveals how berberine protects the heart in diabetes by activating cellular cleanup of harmful fat accumulation.
New research reveals finerenone may reduce new-onset atrial fibrillation in heart failure patients with preserved ejection fraction.
A comprehensive review reveals tirzepatide improves blood pressure, lipids, liver fat, kidney function, and slashes 10-year cardiovascular risk by up to 23.5%.
Scientists discover targeting two cellular pathways simultaneously could overcome treatment resistance in neuroendocrine tumors.
A 2025 review maps the molecular drivers of cardiac aging and evaluates drugs, CRISPR, stem cells, and lifestyle as countermeasures.
The first disease-specific treatment for Barth syndrome gains FDA accelerated approval, targeting mitochondrial dysfunction to restore muscle strength.
A Phase 2 trial tests whether a fixed-dose combination pill can safely lower LDL cholesterol in people with type 2 diabetes.
Sotatercept reduced dangerous pressure in heart failure patients' lungs and improved walking ability in phase 2 study.
Breakthrough anti-fibril depleters could revolutionize treatment for transthyretin amyloid cardiomyopathy, a deadly heart condition.
Enlicitide, a daily pill, dramatically reduced LDL cholesterol in patients with familial hypercholesterolemia beyond what statins alone achieved.
Amgen's siRNA therapy olpasiran targets lipoprotein(a), a stubborn cardiovascular risk factor with no approved treatments.
